Cargando…

Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission

This study presents the final report of the multicenter, prospective tyrosine kinase inhibitor discontinuation study, D‐STOP, after a 3‐year follow‐up of 54 patients with chronic CML who discontinued dasatinib after a sustained deep molecular response (DMR) for ≥2 years with dasatinib treatment. Est...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumagai, Takashi, Nakaseko, Chiaki, Nishiwaki, Kaichi, Yoshida, Chikashi, Ohashi, Kazuteru, Takezako, Naoki, Takano, Hina, Kouzai, Yasuji, Murase, Tadashi, Matsue, Kosei, Morita, Satoshi, Sakamoto, Junichi, Wakita, Hisashi, Sakamaki, Hisashi, Inokuchi, Koiti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419041/ https://www.ncbi.nlm.nih.gov/pubmed/32614159 http://dx.doi.org/10.1111/cas.14518

Ejemplares similares

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation
por: Kumagai, Takashi, et al.
Publicado: (2017)

Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy
por: Shiseki, Masayuki, et al.
Publicado: (2017)

The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group
por: Iriyama, Noriyoshi, et al.
Publicado: (2017)

Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström’s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance
por: Nakamura, Ayako, et al.
Publicado: (2019)

Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
por: Takahashi, Naoto, et al.
Publicado: (2018)

Efficacy and tolerability of Entecavir for hepatitis B virus infection after hematopoietic stem cell transplantation
por: Aoki, Jun, et al.
Publicado: (2014)

Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study
por: Yoshida, Chikashi, et al.
Publicado: (2023)

A mathematical model for dynamics of soluble form of DNAM-1 as a biomarker for graft-versus-host disease
por: Goshima, Yuki, et al.
Publicado: (2020)

Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study
por: Mizuta, Shuichi, et al.
Publicado: (2018)

Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR(4.5)): The phase 2, multicenter N‐Road study
por: Nishiwaki, Kaichi, et al.
Publicado: (2020)

Longer Cortical Silent Period Length Is Associated to Binge Eating Disorder: An Exploratory Study
por: Antunes, Luciana C., et al.
Publicado: (2020)

T-cell lymphoma with a granulomatous lesion of the lungs after autologous hematopoietic stem cell transplantation for Epstein–Barr virus-positive diffuse large B-cell lymphoma: a unique rare case of metachronous B-cell and T-cell lymphoma
por: Kajimoto, Yusuke, et al.
Publicado: (2020)

Successful Control of Dasatinib-related Chylothorax by the Japanese Herbal Medicine “Goreisan”
por: Sasaki, Hisashi, et al.
Publicado: (2019)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Acute Fibrinous and Organizing Pneumonia with Myelodysplastic Syndrome: Corticosteroid Monotherapy Led to Successful Ventilator Weaning
por: Yamamoto, Mari, et al.
Publicado: (2016)

The sensitivity of the FLT3-ITD detection method is an important consideration when diagnosing acute myeloid leukemia
por: Sakaguchi, Masahiro, et al.
Publicado: (2020)

Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM
por: Sunami, Kazutaka, et al.
Publicado: (2020)

Dasatinib-Related Chylothorax
por: Huang, Yen-Min, et al.
Publicado: (2015)

DASATINIB-RELATED CHYLOTHORAX
por: Young, Katherine, et al.
Publicado: (2019)

Comparison of Silent and Conventional MR Imaging for the Evaluation of Myelination in Children
por: Matsuo-Hagiyama, Chisato, et al.
Publicado: (2016)

Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2021)

Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity
por: Suzuki, Kazuhito, et al.
Publicado: (2021)

Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)

Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib
por: Takekoshi, Daisuke, et al.
Publicado: (2020)

Haemorrhagic Colitis Caused by Dasatinib
por: Patodi, Nishant, et al.
Publicado: (2012)

Dasatinib-induced Pulmonary Hypertension
por: Tamura, Yudai, et al.
Publicado: (2022)

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2020)

Effect of further substitutions at 5-, 6-, 7-, or 8-position of 3-[3-(4-methoxyphenyl)-1-hydroxyprop-2-yl]coumarin on phytotoxicity
por: Yamauchi, Satoshi, et al.
Publicado: (2023)

A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities
por: Nekoukar, Zahra, et al.
Publicado: (2021)

A primary esophageal MALT lymphoma patient with Helicobacter pylori infection achieved complete remission after H. pylori eradication without anti-lymphoma treatment
por: Moriya, Keiichi, et al.
Publicado: (2016)

Reversible ventricular arrythmia induced by dasatinib
por: Spechbach, Hervé, et al.
Publicado: (2013)

Predictive biomarkers for dasatinib treatment in melanoma
por: Eustace, Alex J., et al.
Publicado: (2014)

Dasatinib induced pleural effusions - Reply
por: AJ Abdulla, Mohammad, et al.
Publicado: (2020)

Dasatinib induced pleuro-pericardial effusion
por: Mishra, Ajay Kumar, et al.
Publicado: (2020)

Dasatinib-Induced Pleural and Pericardial Effusions
por: Hailan, Yousef M, et al.
Publicado: (2021)

Dasatinib-Induced Bilateral Pleural Effusions
por: Rasul, Taha F, et al.
Publicado: (2022)

Severe rhabdomyolysis and SARS-CoV-2 vaccination: a reply to the letter by Dr. Josef Finsterer.: Reply to Letter to the Editor regarding our report to Dr. Finsterer.
por: Kamura, Yuya, et al.
Publicado: (2022)

Soluble DNAM-1, as a Predictive Biomarker for Acute Graft-Versus-Host Disease
por: Kanaya, Minoru, et al.
Publicado: (2016)

Identification and Characterization of Bifunctional Proline Racemase/Hydroxyproline Epimerase from Archaea: Discrimination of Substrates and Molecular Evolution
por: Watanabe, Seiya, et al.
Publicado: (2015)

A New Diterpene from Litsea cubeba Fruits: Structure Elucidation and Capability to Induce Apoptosis in HeLa Cells
por: Trisonthi, Piyapat, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7u17n19h6g1ldml3h88l0d63qv